Rapid-response manufacturing of adenovirus-vectored vaccines by Joe, CCD, Chopra, N, Nestola, P, Niemann, J, Douglas, AD

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four random... by Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs by Joe, CCD, Jiang, J, Linke, T, Li, Y, Fedosyuk, S, Gupta, G, Berg, A, Segireddy, RR, Mainwaring, D, Joshi, A, Cashen, P, Rees, B, Chopra, N, Nestola, P, Humphreys, J, Davies, S, Smith, N, Bruce, S, Verbart, D, Bormans, D, Knevelman, C, Woodyer, M, Davies, L, Cooper, L, Kapanidou, M, Bleckwenn, N, Pappas, D, Lambe, T, Smith, DC, Green, CM, Venkat, R, Ritchie, AJ, Gilbert, SC, Turner, R, Douglas, AD

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK by Voysey, M, Clemens, SAC, Madhi, SA, Weckx, LY, Folegatti, PM, Aley, PK, Angus, B, Baillie, VL, Barnabas, SL, Bhorat, QE, Bibi, S, Briner, C, Cicconi, P, Collins, AM, Colin-Jones, R, Cutland, CL, Darton, TC, Dheda, K, Duncan, CJA, Emary, KRW, Ewer, KJ, Fairlie, L, Faust, SN, Feng, S, Ferreira, DM, Finn, A, Goodman, AL, Green, CM, Green, CA, Heath, PT, Hill, C, Hill, H, Hirsch, I, Hodgson, SHC, Izu, A, Jackson, S, Jenkin, D, Joe, CCD, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, AM, Lelliott, A, Libri, V, Lillie, PJ, Mallory, R, Mendes, AVA, Milan, EP, Minassian, AM, Lambe, T, Pollard, AJ

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial by Ramasamy, MN, Minassian, AM, Ewer, KJ, Flaxman, AL, Folegatti, PM, Owens, DR, Voysey, M, Aley, PK, Angus, B, Babbage, G, Belij-Rammerstorfer, S, Berry, L, Bibi, S, Bittaye, M, Cathie, K, Chappell, H, Charlton, S, Cicconi, P, Clutterbuck, EA, Colin-Jones, R, Dold, C, Emary, KRW, Fedosyuk, S, Fuskova, M, Gbesemete, D, Green, C, Hallis, B, Hou, MM, Jenkin, D, Joe, CCD, Kelly, EJ, Kerridge, S, Lawrie, AM, Lelliott, A, Lwin, MN, Makinson, R, Marchevsky, NG, Mujadidi, Y, Munro, APS, Pacurar, M, Plested, E, Rand, J, Rawlinson, T, Rhead, S, Robinson, H, Ritchie, AJ, Ross-Russell, AL, Saich, S, Singh, N, Pollard, AJ, Oxford COVID Vaccine Trial Group